The market for biotherapeutics is continually expanding as the pipeline for small molecules dries up. Early stage identification and characterization of those clones producing high levels of the therapeutic protein of interest is mandatory from a productivity standpoint. Despite the technical limitations of traditional ELISA —such as low throughput and limited reproducibility—many labs still rely on this approach to carry out assays on recombinant proteins, such as IgG clonal selection and characterization, which can hamper the identification of the best candidate drugs. In this webinar, our expert panel will review how new technologies can be used to analyze recombinant protein expression, maturation, and secretion.
During the webinar, you will:
- Hear about how the latest technologies are being applied to identify the optimal expression clones
- See recent data presented by our experts on their current projects
- Have your questions answered live during the webinar!
For related products/technologies, go to: www.perkinelmer.com/biotherapeutics